Michael P. Bogenschutz, MD

home / authors / michael-p-bogenschutz-md

Articles

Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.

Acute Mind-Altering Effects of Psilocybin Managed With Clinician Oversight

Michael P. Bogenschutz, MD
January 10th 2025

Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.

Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.

Integrating PAP into Comprehensive Cancer Care for Mental Health

Michael P. Bogenschutz, MD
January 9th 2025

Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.

Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.

Psilocybin May Help Alleviate Cancer-Related Depressive Symptoms

Michael P. Bogenschutz, MD
January 9th 2025

Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.

Latest Updated Articles

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Published: March 1st 2018 | Updated: January 18th 2025
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
4 experts are featured in this series.
Published: January 13th 2025 | Updated: January 18th 2025
ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant